▲ Peaking
Business
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.
Coverage by STAT as tracked by Newsylist.
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.
New research suggests statins and blood pressure medications are narrowing the heart risk gap between adults with obesity and those of a healthy weight.